Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerMolecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsDiagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung CancerDifferential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer.Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceImpact of multimodality approach for patients with leptomeningeal metastases from solid tumorsAfatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysisRapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report.The diagnosis and treatment of brain metastases in EGFR mutant lung cancer.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Osimertinib for the treatment of non-small cell lung cancer.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation.Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study.Leptomeningeal disease: current diagnostic and therapeutic strategies.Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms.High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.[Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.Elemene treatment for NSCLC with multiple CNS metastases: a case report and literature reviewGefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
P2860
Q26740529-CEB6C59F-F13F-47D5-8758-5EC0D216ED27Q26741320-5FD3C72D-968B-48A7-8356-CBF45F33C10EQ26781690-821920AF-29BA-412A-B949-02F69F2DF1BDQ33583253-C05F2798-E46C-463E-9FCC-C5482E1295EEQ33626335-B3812856-457D-40F6-B0DB-AA4337D30E1FQ34011705-D24F85F0-4EEB-4AB8-BFDA-7A3ED7205009Q34029965-D62C8354-2779-4027-9D3C-6C5264A489D4Q36195658-82DFE439-BAFC-42CA-95FB-C91349126055Q37107954-31EC0F1C-EC33-4F73-8398-120B3F5416B9Q37355963-7BBA2EB8-204D-45A7-A98A-27C3B94CD1E1Q38233179-721BF9D7-08CA-42B5-80E0-E9A09A05A798Q38763111-1E5DC282-3F20-4D7A-BE69-2B2666E2E4FDQ39002726-7A43430E-643A-4795-8326-DFCB2119B190Q39179464-D6052E66-3045-40A2-8966-2835789908CCQ39556310-07B06454-300A-4242-A18A-7CBC7FB69971Q40381138-FFB6805F-8563-4188-B744-1B64646AAE00Q40498874-61EE6F4E-4C4F-41D1-A37C-5B9FB3CF7C90Q41067539-8D7FA183-5837-4BEA-8CE8-2E3BD7CB4460Q42700664-18E48846-BA2A-4AF3-B2DE-C2D26C98D1AFQ46108334-BD854C2F-B0EE-4C52-8B45-3416E15FA2CBQ47730834-CC8B719B-23E9-4B9F-B34E-6E89CBBE2CC6Q48379492-125F8BEE-99AA-43B1-A233-7ACD5552BEA4Q48551119-F91EBDC0-39FC-4C3B-A08A-D113C2E2A987Q49894049-283D7D39-CBF8-44A9-B305-42409988B073Q51636097-684E2B55-FC01-4799-B094-7DBA31EF4EFFQ52559905-E0996399-206A-432D-8762-31D0175B96E7Q54115504-A5C97591-0F76-414F-82E0-F61444CDBFDBQ54143053-5026F337-3475-4767-8DB2-590AE681EE53Q54219749-5A6650C4-2214-4E4D-BC95-1B507611CC4CQ54989107-AEF41900-17DD-4FCF-A153-B46D62DB419AQ55327976-ECEDBC62-2044-4B91-A408-171DBA270458Q57485207-42313BCE-D8CF-46C9-B521-7559BAE5C3B2Q58803156-93FA5E6D-A1A3-4BDB-B51A-D53F507B23B5
P2860
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@en
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@nl
type
label
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@en
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@nl
prefLabel
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@en
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@nl
P2093
P1476
Erlotinib versus gefitinib for ...... in non-small-cell lung cancer.
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Dong-Wan Kim
Doo Hyun Chung
Eunyoung Lee
Se-Hoon Lee
Tae Min Kim
P304
P356
10.1097/JTO.0B013E318294C8E8
P577
2013-08-01T00:00:00Z